R&D Pipeline

Phase:
Therapy:
Pipeline last updated 29 October 2015
Compound/Indication
Phase123
Xultophy® (NN9068) Type 2 diabetes
N9-GP (NN7999) Haemophilia B
Semaglutide (NN9535) Type 2 diabetes
N8-GP (NN7088) Haemophilia A
Somapacitan (NN8640) Growth disorder
Oral semaglutide (NN9924) Type 2 diabetes
OI338GT (NN1953) Type 1 and 2 diabetes
Anti-IL 21 T1D (NN9828) Type 1 diabetes
Dual-agonist (NN9709) Type 2 diabetes
LAI287 (NN1436) Type 1 and 2 diabetes
Prandial (NN1406) Type 1 and 2 diabetes
OI320GT (NN1957) Type 2 diabetes
PYY 1562 (NN9748) Type 2 diabetes
AM833 (NN9838) Obesity
G530L (NN9030) Obesity
Concizumab (NN7415) Haemophilia A and B